Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a Healthcare company (Medical - Devices) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Integra LifeSciences Holdings Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $13.55, Integra LifeSciences Holdings Corporation trades at 80.9x trailing earnings, 0.6x sales and 1.0x book value, with an EV/EBITDA of 12.0. Over the last twelve months it generated about $1.7B of revenue and $13M of net income. It runs a gross margin of 52.5%, an operating margin of 38.3% and a net margin of 0.8%. It shows return on equity of 1.2%, return on invested capital of 11.4% and a free cash flow yield of 6.8%. On the balance sheet: a debt-to-equity ratio of 1.88 and a current ratio of 3.62. Over the past 52 weeks the share price ranged from $8.70 to $20.49, with a beta of 1.28.
Integra LifeSciences Holdings Corporation does not currently pay a dividend.
28 Wall Street analyst ratings cover the stock: 12 Buy, 12 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Integra LifeSciences Holdings Corporation (IART) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 157.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.8% / 30% · Interest income / Revenue 1.22% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 157.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.8% / 33% · Receivables / Mkt Cap (36m) 21.4% / 49% · Interest income / Revenue 1.22% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 157.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.8% / 33.33% · Receivables / Mkt Cap (24m) 21.4% / 33.33% · Interest income / Revenue 1.22% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 51.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.81% / 33.33% · Receivables / Avg Assets (4Q) 7.42% / 33.33% · Interest income / Revenue 1.22% / 5% | Fail |
| FTSE | Debt / Total Assets 52.1% / 33.33% · (Cash+ST Inv) / Total Assets 8.89% / 33.33% · (Cash+Recv) / Total Assets 16.0% / 33.33% · Interest income / Revenue 1.22% / 5% | Fail |
No. As of September 2026, Integra LifeSciences Holdings Corporation (IART) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Integra LifeSciences Holdings Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 1.22% of each dividend: Integra LifeSciences Holdings Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.